The efficacy of VUMERITY is based upon bioavailability studies comparing dimethyl fumarate to VUMERITY in healthy subjects and patients with RMS1

Dimethyl fumarate Significantly Reduced Brain Lesion Activity1-4

A relationship between MRI findings and clinical outcomes in RMS has not been established.

≥80% of Patients Taking dimethyl fumarate Had 0 Gd+ Lesions at 2 Years1

Percentage of subjects with Gd+ lesions at 2 years